AVITA Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

AVITA Medical şirketinin toplam hissedar öz sermayesi $12.2M ve toplam borcu $42.5M olup, bu da borç-öz sermaye oranını 348% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $81.1M ve $68.8M dir.

Anahtar bilgiler

348.0%

Borç/özkaynak oranı

US$42.55m

Borç

Faiz karşılama oranı	n/a
Nakit	US$44.41m
Eşitlik	US$12.23m
Toplam yükümlülükler	US$68.82m
Toplam varlıklar	US$81.05m

Son finansal sağlık güncellemeleri

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18

Recent updates

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RCEL 'nin kısa vadeli varlıkları ( $63.9M ) kısa vadeli yükümlülüklerini ( $17.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: RCEL şirketinin kısa vadeli varlıkları ( $63.9M ) uzun vadeli yükümlülüklerini ( $51.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RCEL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: RCEL şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 348% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RCEL şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: RCEL tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

AVITA Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Recent updates

AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024

Third quarter 2024 earnings: EPS misses analyst expectations

Forecast to breakeven in 2026

AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 18%

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

New minor risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Shareholder dilution

AVITA Medical, Inc. Announces Executive Changes

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

New minor risk - Shareholder dilution

AVITA Medical, Inc. Announces FDA Approval of RECELL GO

Consensus EPS estimates fall by 19%

No longer forecast to breakeven

AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

New minor risk - Share price stability

AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024

AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024

Forecast to breakeven in 2026

New minor risk - Insider selling

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC

AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go

AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo

AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair

AVITA Medical, Inc. Revises Financial Guidance for the Year 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair

AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces Chief Executive Officer Changes

Avita Medical appoints James Corbett as CEO

AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

RECELL Insurance Coverage Begins in Japan for Acute Burns

Avita's burn therapy Recell gets insurance coverage in Japan following approval

AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index

Avita Medical, Inc. Provides Guidance for Year 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022

AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy

AVITA Medical Is Interesting, But Not Just Yet